- Home
- PRLD vs IMAB Comparison
PRLD vs IMAB Comparison
Compare PRLD & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRLD
- IMAB
- Stock Information
- Founded
- PRLD 2016
- IMAB 2014
- Country
- PRLD United States
- IMAB United States
- Employees
- PRLD N/A
- IMAB N/A
- Industry
- PRLD Medicinal Chemicals and Botanical Products
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- PRLD Health Care
- IMAB Health Care
- Exchange
- PRLD Nasdaq
- IMAB Nasdaq
- Market Cap
- PRLD 73.7M
- IMAB 79.9M
- IPO Year
- PRLD 2020
- IMAB 2020
- Fundamental
- Price
- PRLD $0.87
- IMAB $0.97
- Analyst Decision
- PRLD Strong Buy
- IMAB Strong Buy
- Analyst Count
- PRLD 2
- IMAB 3
- Target Price
- PRLD $4.50
- IMAB $8.00
- AVG Volume (30 Days)
- PRLD 200.4K
- IMAB 270.1K
- Earning Date
- PRLD 03-04-2025
- IMAB 03-13-2025
- Dividend Yield
- PRLD N/A
- IMAB N/A
- EPS Growth
- PRLD N/A
- IMAB N/A
- EPS
- PRLD N/A
- IMAB N/A
- Revenue
- PRLD $3,000,000.00
- IMAB $569,464.00
- Revenue This Year
- PRLD N/A
- IMAB N/A
- Revenue Next Year
- PRLD N/A
- IMAB N/A
- P/E Ratio
- PRLD N/A
- IMAB N/A
- Revenue Growth
- PRLD N/A
- IMAB N/A
- 52 Week Low
- PRLD $0.80
- IMAB $0.84
- 52 Week High
- PRLD $6.80
- IMAB $2.00
- Technical
- Relative Strength Index (RSI)
- PRLD 37.59
- IMAB 46.51
- Support Level
- PRLD $0.87
- IMAB $0.96
- Resistance Level
- PRLD $1.01
- IMAB $1.04
- Average True Range (ATR)
- PRLD 0.08
- IMAB 0.05
- MACD
- PRLD -0.02
- IMAB -0.00
- Stochastic Oscillator
- PRLD 0.90
- IMAB 36.36
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).